This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
by Zacks Equity Research
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change EVAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
International Consolidated Airlines Group SA (ICAGY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ICAGYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
BMYNegative Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechnology biotechs medical pharmaceuticals
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
by Zacks Equity Research
Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.
ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change IRONPositive Net Change
biotechnology biotechs pharmaceuticals
Agilent (A) Boosts LSAG Segment With Advanced Dilution System
by Zacks Equity Research
Agilent (A) unveils ADS 2 to enhance workflow efficiency within the laboratory, boosting the LSAG segment.
APositive Net Change AMEPositive Net Change AMATPositive Net Change BLPositive Net Change
biotechnology tech-stocks
Fuel Tech, Inc. (FTEK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
FTEKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
by Zacks Equity Research
SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals have been highlighted in this Investment Ideas article.
IBBPositive Net Change VKTXPositive Net Change XBIPositive Net Change MDGLPositive Net Change
biotechnology
After Golden Cross, J.Jill (JILL)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
JILLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
McEwen (MUX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MUXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
2 Top Biotech Buyout Candidates
by Andrew Rocco
The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities
NVOPositive Net Change LLYPositive Net Change IBBPositive Net Change VKTXPositive Net Change XBIPositive Net Change MDGLPositive Net Change
biotechnology biotechs pharmaceuticals
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
by Zacks Equity Research
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change APGEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
by Ekta Bagri
Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.
REGNNegative Net Change MRNAPositive Net Change VKTXPositive Net Change PRAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
ACETPositive Net Change ADMAPositive Net Change AKBAPositive Net Change FGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
by Zacks Equity Research
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
VRTXPositive Net Change HTGCPositive Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
by Zacks Equity Research
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
NVSPositive Net Change INCYNegative Net Change ADMAPositive Net Change MESOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Praxis (PRAX) Surges on Positive Epilepsy Study Results
by Zacks Equity Research
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change PRAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ALGSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
by Zacks Equity Research
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
ACETPositive Net Change ADMAPositive Net Change FGENPositive Net Change STOKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline
by Zacks Equity Research
Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.
AZNPositive Net Change NVOPositive Net Change ADMAPositive Net Change FUSNPositive Net Change
biotechnology medical pharmaceuticals
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
by Zacks Equity Research
Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
REGNNegative Net Change ANIPPositive Net Change ADMAPositive Net Change GLPGPositive Net Change
biotechnology biotechs medical pharmaceuticals
After Golden Cross, Shell (SHEL)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SHELPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
OPENLANE (KAR) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
KARPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
by Tirthankar Chakraborty
Invest in growth stocks such as American Eagle Outfitters (AEO), Abercrombie & Fitch (ANF), Cimpress (CMPR), Dianthus Therapeutics (DNTH) and NVIDIA (NVDA) as the stock market is well-poised to scale upward.
ANFPositive Net Change AEOPositive Net Change NVDAPositive Net Change CMPRPositive Net Change DNTHPositive Net Change
biotechnology consumer-discretionary retail semiconductor
Wall Street Set to Post Fifth Winning Month Amid Volatility
by Zacks Equity Research
Wall Street is likely to record the fifth consecutive winning month despite volatility.
BAPositive Net Change INTCPositive Net Change AMDPositive Net Change NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change
aerospace biotechnology semiconductor
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
by Zacks Equity Research
Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
PFEPositive Net Change BAYRYPositive Net Change BBIONegative Net Change
biotechnology biotechs pharmaceuticals